

E3
B1
CD133

44. (New) The method of claim 42, wherein said late acting cytokines are selected from the group consisting of granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor and erythropoietin.

45. (New) The method of claim 37, wherein said cells are derived from a source selected from the group consisting of bone marrow, peripheral blood and neonatal umbilical cord blood.

46. (New) The method of claim 37, wherein said cells are enriched for hematopoietic CD34⁺ cells.

47. (New) The method of claim 37, wherein said cells are selected from the group consisting of non-differentiated stem cells and committed progenitor cells.

REMARKS

Election

The Examiner required election between Group I (claims 1-15 and 26-36) and Group II (claims 16-25). By an amendment filed January 18, 2001, Applicant canceled claims 16-36, thereby eliminating Group II from the application. Accordingly, Applicant's amendment complied with the restriction requirement by electing the claims of Group I.

New Claims

New claims 37-47, corresponding to previously canceled claims 26-36 and belonging to Group 1 are hereby added.

Sequence Listing

Enclosed please find a nucleotide and/or amino acid listing in a computer readable form.

Statement

The content of the paper and computer readable form are the same and include no new matter.

Respectfully submitted,



Sol Sheinbein
Attorney for Applicant
Registration No. 25,457

Date: March 22, 2001.

Encl.:

CRF of Sequence Listing; and
One month extension fees.